Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 156.53 | 138.03 | 130.40 | 95.91 | 85 |
Total Expenses | 140.63 | 121.15 | 111.47 | 82.68 | 72.77 |
Profit Before Tax | 15.90 | 16.88 | 18.93 | 13.23 | 12.23 |
Profit After Tax | 11.67 | 12.76 | 15.18 | 10.68 | 9.62 |
Operating Profit after Depreciation | 23.49 | 22.83 | 21.83 | 15.72 | 14.48 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 314.29 | 266.64 | 204.65 | 69.10 | 65.69 |
Total Non Current Assets | 317.05 | 280.42 | 217.74 | 144.07 | 93.46 |
Total Current Assets | 71.61 | 55.92 | 50.02 | 33.72 | 21.58 |
TOTAL ASSETS | 388.66 | 336.34 | 267.76 | 177.79 | 115.04 |
Total Shareholder's Fund | 262.33 | 173.35 | 127.46 | 98.45 | 81.32 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 24.47 | 33.34 | 35.70 | 14.58 | 18.86 |
Net Cash used in Investing Activities | -51.54 | -74.38 | -90.37 | -46.83 | -22.41 |
Net Cash used in Financing Activities | 27.44 | 41.10 | 54.62 | 32.03 | 3.48 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 156.53 | 138.03 | 130.40 | 95.91 | 85 |
Total Expenses | 140.63 | 121.15 | 111.39 | 82.67 | 72.77 |
Profit Before Tax | 15.90 | 16.88 | 19.01 | 13.24 | 12.23 |
Profit After Tax | 11.67 | 12.76 | 15.24 | 10.69 | 9.62 |
Operating Profit after Depreciation | 23.49 | 22.83 | 21.91 | 15.72 | 14.48 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 314.29 | 266.64 | 204.65 | 69.10 | 65.69 |
Total Non Current Assets | 317.06 | 280.43 | 217.75 | 144 | 93.47 |
Total Current Assets | 71.69 | 55.99 | 50.10 | 33.80 | 21.65 |
TOTAL ASSETS | 388.74 | 336.42 | 267.85 | 177.80 | 115.12 |
Total Shareholder's Fund | 262.42 | 173.43 | 127.54 | 98.46 | 81.32 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 24.47 | 33.34 | 35.79 | 14.58 | 18.79 |
Net Cash used in Investing Activities | -51.54 | -74.38 | -90.40 | -46.83 | -22.34 |
Net Cash used in Financing Activities | 27.44 | 41.10 | 54.56 | 32.03 | 3.48 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 42.78 | 41.15 | 43.06 | 37.23 | 34.08 |
Total Expenses | 31.28 | 30.45 | 32.09 | 28.22 | 24.72 |
Profit Before Tax | 5.11 | 4.70 | 4.79 | 3.01 | 4.15 |
Profit After Tax | 4.80 | 2.41 | 3.12 | 2.07 | 3.64 |
Operating Profit after Depreciation | 11.87 | 11.16 | 11.74 | 9.24 | 10.02 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 42.78 | 41.15 | 43.06 | 37.23 | 34.08 |
Total Expenses | 31.28 | 30.45 | 32.09 | 28.22 | 24.72 |
Profit Before Tax | 5.11 | 4.70 | 4.79 | 3.01 | 4.15 |
Profit After Tax | 4.80 | 2.41 | 3.12 | 2.07 | 3.64 |
Operating Profit after Depreciation | 11.87 | 11.16 | 11.74 | 9.24 | 10.02 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Sakar Healthcare Ltd | ₹273.60 | ₹595.08 |
Sun Pharmaceuticals Industries Ltd | ₹1,745.25 | ₹4,18,743.94 |
Divis Laboratories Ltd | ₹5,733.60 | ₹1,52,209.07 |
Cipla Ltd | ₹1,458.15 | ₹1,17,762.24 |
Torrent Pharmaceuticals Ltd | ₹3,357.15 | ₹1,13,616.11 |
Mankind Pharma Ltd | ₹2,488.40 | ₹1,02,663.15 |
18 Oct 2024, 04:55 pm
09 Aug 2024, 04:37 pm
23 Jul 2024, 10:02 am
15 May 2024, 04:27 pm
06 Mar 2024, 12:19 pm